Soll says that the reason for the success of the DSHB is low cost and reliability, achieved through proprietary methods of production and distribution that he and his staff have developed over the last 12 years. The NIH created the DSHB in 1986 at Johns Hopkins University, with a subcontract to the late Michael Solursh at the UI. In 1995 Soll negotiated transfer of the entire bank to his lab at the UI. The DSHB was designed to distribute hybridomas and monoclonal antibodies at cost to developmental biologists to advance research. Since moving to Soll's laboratory in 1995, where it became self-supporting in six months, the collection has increased three-fold and the number of filled requests has increased by 700 percent to more than 800 per month, while the prices have remained stable at roughly one-tenth commercial fees.
"My intention was, and still is, to keep the price of monoclonals low so that researchers can test multiple monoclonals without commitment of significant funds," Soll says. "A second intent is to relieve scientists of the time and expense of distributing monoclonals they have developed. A third intent is to assure the scientific community that monoclonals with limited demand still remain available. I have strived over these many years to expand the DSHB and remain true to its mission."
Hybridomas, the stock and trade of the bank, are cells that produce unique antibodies that bind to specific molecules, making them extraordinarily powerful tools for scientists. Monoclonals are increasingly being used as diagnostics for cancer and other diseases, and are emerging as powerful, but highly expensive, therapeutic drugs. Un
'/>"/>
| Contact: Gary Galluzzo gary-galluzzo@uiowa.edu 319-384-0009 University of Iowa Source:Eurekalert |